London, United Kingdom

Charles Akle

USPTO Granted Patents = 11 


 

Average Co-Inventor Count = 2.8

ph-index = 3

Forward Citations = 29(Granted Patents)


Location History:

  • London, GB (2013 - 2022)
  • Uxbridge, GB (2021 - 2024)

Company Filing History:


Years Active: 2013-2024

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Charles Akle: Innovator in Cancer Therapy

Introduction

Charles Akle is a prominent inventor based in London, GB. He has made significant contributions to the field of cancer therapy, holding a total of 11 patents. His work focuses on developing innovative immunomodulators aimed at treating neoplastic diseases.

Latest Patents

Among his latest patents are groundbreaking inventions such as a checkpoint inhibitor and a whole cell for use in cancer therapy. This immunomodulator is designed for the treatment, reduction, inhibition, or control of neoplastic diseases in patients undergoing checkpoint inhibition therapy. It can be administered simultaneously, separately, or sequentially with the immunomodulator. Another notable patent involves an immunogenic treatment of cancer, which provides an immunomodulator for the treatment and control of neoplastic diseases. This therapy can utilize various methods, including microwave irradiation, targeted radiotherapy, and photodynamic therapy, among others.

Career Highlights

Charles Akle is associated with Immodulon Therapeutics Limited, where he continues to advance his research and development efforts. His innovative approaches have positioned him as a key figure in the fight against cancer.

Collaborations

He has collaborated with notable colleagues such as John Grange and Kevin Bilyard, contributing to the advancement of cancer treatment technologies.

Conclusion

Charles Akle's work in developing immunomodulators for cancer therapy showcases his dedication to innovation in medical science. His contributions are paving the way for new treatment options for patients facing neoplastic diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…